Pheochromocytoma classification: Difference between revisions
Asem Juhani (talk | contribs) No edit summary |
Asem Juhani (talk | contribs) |
||
| Line 11: | Line 11: | ||
* [[Malignant]]: 10% of pheochromocytomas are [[malignant]]. | * [[Malignant]]: 10% of pheochromocytomas are [[malignant]]. | ||
[[Malignant]] and [[benign]] [[Tumor|tumors]] share the same [[biochemical]] and [[histological]] characters. The only difference is the ability of the [[malignant]] [[tumor]] to invade local and distant [[Tissue (biology)|tissues]] according to [[World Health Organization|WHO]] Classification of [[Tumor|tumors]].<ref name="pmid26291008">{{cite journal| author=Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB et al.| title=The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. | journal=J Thorac Oncol | year= 2015 | volume= 10 | issue= 9 | pages= 1243-60 | pmid=26291008 | doi=10.1097/JTO.0000000000000630 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26291008 }}</ref> | |||
Most cases need follow up for a long duration. | |||
=== '''Classification based on spread:''' === | === '''Classification based on spread:''' === | ||
Revision as of 20:08, 7 February 2019
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma classification On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma classification |
|
Risk calculators and risk factors for Pheochromocytoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytomas and paragangliomas (collectively referred to as PPGLs) are rare tumors that originate from chromaffin cells in the adrenal medulla (pheochromocytoma) or in the extra-adrenal neural ganglia (paraganglioma). These tumors can be either biochemically active (producing a catecholamine like epinephrine, nor-epinephrine and dopamine) or biochemically silent. PPGLs can be either sporadic or genetic, with association to several familial syndromes.
PPGLs can also be classified according to their spread into local, regional, or metastatic. The definition of malignancy in PPGLs is the presence of metastasis.
Classification
Classification based on nature of tumor:
Malignant and benign tumors share the same biochemical and histological characters. The only difference is the ability of the malignant tumor to invade local and distant tissues according to WHO Classification of tumors.[1] Most cases need follow up for a long duration.
Classification based on spread:
- Localized:
- 95% of pheochromocytomas are found in the abdomen
- 85 to 90 % are intra-adrenal
- 5 to 10 percent are multiple
- 10% are extra-adrenal and are referred to as catecholamine-secreting paragangliomas.
- Regional
- Metastatic:
Classification based on genetics:
Familial pheochromocytoma
- Familial pheochromocytoma is associated with multiple endocrine neoplasia 1 (MEN1) and multiple endocrine neoplasia 2B (MEN2B), which are autosomal dominant syndromes, caused by a mutation in the menin and RET genes, respectively. Pheochromocytoma occurs in 50% of patients with MEN2B.
- The MEN1 and MEN2B syndromes consist of the following features:
Non-familial pheochromocytoma:
- The majority of them are positive for KIT expression, some are not. A partial explanation was provided by the finding of activating mutations in another gene encoding an RTK, the platelet-derived growth factor receptor alpha (PDGFRA) gene in some KIT-negative GISTs:
Sporadic:
- Most catecholamine-secreting tumors are sporadic. Mutations have been identified in most of the sporadic cases.
- May be due to spontaneous mutation, decreased penetrance or maternal imprinting.[2]
- 50% of patients had a pathogenic mutation in SDHB, SDHD, or VHL.[3]
References
- ↑ Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB; et al. (2015). "The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification". J Thorac Oncol. 10 (9): 1243–60. doi:10.1097/JTO.0000000000000630. PMID 26291008.
- ↑ Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N; et al. (2012). "A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma". Horm Metab Res. 44 (5): 359–66. doi:10.1055/s-0032-1304594. PMID 22517557.
- ↑ Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV; et al. (2013). "Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma". Clin Endocrinol (Oxf). 78 (6): 898–906. doi:10.1111/cen.12074. PMID 23072324.